COMP <GO>
CRON vs TRLV // EV/EBITDA & P/E VALUATION
Cronos Group Inc. Common Share (NASDAQ) VS. Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE) • 15-METRIC TALLY: CRON 4
— TRLV 5
■ METRIC PARITY
LAST: $3.36 (+0.30%) • MKT CAP: $1.24B
valuation
—
LAST: $10.60 (-0.19%) • MKT CAP: $2.04B
valuation
9.9x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRON VS. TRLV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRON | TRLV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 42.80% | 60.20% | -17.40 | TRLV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.50% | 12.80% | -17.30 | TRLV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 9.9x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.01% | 11.20% | -11.19 | TRLV | /fcf-yield <GO> |
| Operating Margin | -11.90% | 12.10% | -24.00 | TRLV | /operating-margins <GO> |
| Net Profit Margin | -2.00% | -9.90% | +7.90 | CRON | /net-margins <GO> |
| Revenue Growth (YoY) | 24.60% | -0.40% | +25.00 | CRON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 15.20 | 1.12 | +14.08 | CRON | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 6/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.4 | 43.3 | +7.13 | CRON | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.24B | $2.04B | -$803.3M | TRLV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRON REV | TRLV REV | CRON GROSS % | TRLV GROSS % | CRON FCF | TRLV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $146.6M | $1.18B | 42.8% | 60.2% | $149.0K | $228.6M |
| FY 2024 | $117.6M | $1.19B | 21.4% | 60.3% | $6.4M | $148.9M |
| FY 2023 | $87.2M | $1.13B | — | — | -$42.8M | $201.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRON // BETA —
TRLV // BETA —